Why is desmopressin banned by WADA?

Desmopressin is on the WADA Prohibited List as a masking agent. By stimulating release of von Willebrand factor, it can alter blood parameters and potentially mask blood doping. It is banned in-competition. Athletes with legitimate medical need (e.g., diabetes insipidus) may apply for a Therapeutic Use Exemption (TUE).

What is the main safety concern with desmopressin?

Hyponatremia (low blood sodium) is the most serious risk. Desmopressin concentrates urine by promoting water reabsorption; if patients drink excessive fluids while on desmopressin, water retention can dilute blood sodium to dangerous levels, causing seizures or cerebral edema. Patients must follow fluid restriction guidelines, especially when starting therapy or changing dose.

Content reviewed by clinical research staff

Last reviewed: March 2026Sources: PubMed, FDA, WADA Prohibited List

Evidence graded using the PeptideScholar A-D system

Desmopressin

AFDA Approved

Moderate Credibility

1 cited studyy · Evidence level A

Vasopressin V2 receptor agonist · 9 amino acids · Brand: DDAVP, Nocdurna, Stimate

FDA ApprovedPrescription RequiredWADA Banned

Desmopressin is a synthetic analog of arginine vasopressin (antidiuretic hormone) with enhanced V2 receptor selectivity and prolonged duration. It is one of the most widely prescribed peptide drugs globally, used for central diabetes insipidus, nocturnal enuresis, and bleeding disorders.

Mechanism of Action

Binds to V2 receptors in renal collecting ducts, increasing aquaporin-2 water channel insertion and water reabsorption. This concentrates urine and reduces urine volume. Also activates V2 receptors on vascular endothelium to release von Willebrand factor, improving platelet function and clotting factor VIII levels.

Benefits

First-line therapy for central diabetes insipidus^[1]
Treats nocturnal enuresis (bedwetting) in children and adults
Controls bleeding in hemophilia A and von Willebrand disease
Well-tolerated with decades of safety data

Not Medical Advice — Research-Reported Information Only

This content is for informational purposes only and does not constitute medical advice.

Desmopressin — Dosing in Published Research

Reported Routes: Oral, Intranasal, Subcutaneous injection, Intravenous

Central DI: 0.1-0.8 mg oral daily in 2-3 divided doses, or 1-2 sprays (10-20 mcg) intranasally daily, or 2-4 mcg SC/IV daily. Nocturnal enuresis: 0.2-0.6 mg oral at bedtime. Hemophilia/VWD: 0.3 mcg/kg IV in 50 mL saline over 15-30 minutes.

The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.

Side Effects

Hyponatremia and water intoxication (most serious risk; fluid restriction required)
Headache, nausea
Nasal congestion (intranasal form)
Hypotension (rare)
Thrombotic events (rare, with IV use in bleeding disorders)

Ready to Discuss Desmopressin with a Doctor?

Desmopressin is FDA-approved and available by prescription. Licensed telehealth providers can evaluate if it's right for you.

Find a Prescribing Provider

Telehealth consultations available in most states

FDA ApprovedBoard-Certified DoctorsPrescription if Appropriate

PeptideScholar may receive compensation from provider referrals. This does not influence our editorial content.

Approved Treatment Routing

Desmopressin in PeptideScholar's current approved-treatment dataset

Desmopressin is currently modeled on this site as an approved treatment path for: Central diabetes insipidus; primary nocturnal enuresis; hemophilia A and von Willebrand disease (Type 1); uremic bleeding. Brand names in the current dataset: DDAVP, Nocdurna, Stimate.

Validation Note

This block reflects the site's current structured treatment data and internal routing logic. It is not a substitute for checking current prescribing, labeling, payer, or local regulatory details.

View treatment routing profiles Use provider matcher Review legal guidance

Research & Evidence

RCTN Engl J Med, 2018

Copeptin in the Diagnosis of Diabetes Insipidus.

Copeptin-based diagnostic approach with hypertonic saline infusion accurately differentiated central DI, nephrogenic DI, and primary polydipsia, validating the central role of AVP deficiency in DI pathophysiology

PMID: 30382699

References

1. Copeptin in the Diagnosis of Diabetes Insipidus.. N Engl J Med, 2018. “Copeptin-based diagnostic approach with hypertonic saline infusion accurately differentiated central DI, nephrogenic DI, and primary polydipsia, validating the central role of AVP deficiency in DI pathophysiology” [PMID: 30382699]

Recommended Resources

The Peptide Protocols Handbook

Evidence-based reference guide covering mechanisms, research, and clinical applications.

View on Amazon

Third-Party Peptide Testing

Independent lab analysis to verify peptide purity and authenticity.

Learn More

Links may be affiliate links. See our disclosure.

GLP-1 Support Essentials

Products to help manage side effects and optimize outcomes during treatment.

LMNT Electrolyte Packets

Sodium-focused electrolytes to prevent dehydration and fatigue common in early GLP-1 therapy.

$30–45View on Amazon

High-Protein Shakes (30g)

Convenient protein shakes to maintain muscle mass on reduced GLP-1 caloric intake.

$28–42View on Amazon

Metamucil Fiber Supplement

Soluble fiber powder to manage constipation and GI side effects during GLP-1 treatment.

$20–30View on Amazon

Vitamin B12 (Methylcobalamin 1000mcg)

GLP-1 agonists can reduce B12 absorption over time — methylcobalamin is the most bioavailable form.

$10–20View on Amazon

Ginger Chews for Nausea

Natural nausea relief for the dose-escalation adjustment period, particularly weeks 1–4.

$8–15View on Amazon

Unflavored Whey Protein Isolate

Preserve lean mass without excess carbs or calories when appetite is suppressed.

$35–60View on Amazon

Amazon affiliate links — we may earn a small commission at no extra cost to you. See our disclosure.

Progress Tracking Tools

Monitor weight, body composition, and nutrition to maximize results.

Smart WiFi Body Scale

Tracks BMI, body fat %, and muscle mass — essential for monitoring GLP-1 progress over time.

$30–60View on Amazon

Digital Kitchen Food Scale

Precise gram-level portion tracking helps maximize weight loss results on GLP-1 therapy.

$10–20View on Amazon

Protein Shaker Bottle Set

Leak-proof mixing bottles for protein shakes — supports consistent protein intake on a smaller appetite.

$12–25View on Amazon

Amazon affiliate links — we may earn a small commission at no extra cost to you. See our disclosure.

Desmopressin FAQ

Medical Disclaimer

This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.

No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.

Get peptide research updates

Weekly evidence summaries and regulatory alerts.

No spam. Unsubscribe anytime.